ArticleOncoimmunology
A novel
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 29 citations in OpenAlex.
- Design and Engineering of Recombinant Oncolytic Adenoviruses Expressing an Anti-EpCAM/Anti-CD3 BiTE for Targeted Immunotherapy of A549 Lung Cancer Cells.OncoTargets and therapy · 2026Article
- A machine learning-based method to optimize the immunogenicity of human leukocyte antigen class I-restricted neoantigens.Briefings in bioinformatics · 2025Article
- Exploring the DNAHeliyon · 2024Article
- Structural and Dynamic-Based Characterization of the Recognition Patterns of E7 and TRP-2 Epitopes by MHC Class I Receptors through Computational Approaches.International journal of molecular sciences · 2024Article
- Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.iScience · 2023Article
- Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models.Molecular therapy oncolytics · 2023Article
- Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies.Cancers · 2023Review
- Article
- An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity.Cancer immunology research · 2022Article
- Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis.Applied bionics and biomechanics · 2022Article
- From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot.Journal of Cancer · 2022Article
- Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.Frontiers in oncology · 2022Review
- Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells.Pharmaceutics · 2021Article
- Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation.Nanotheranostics · 2021Article
- Review
- Selecting Target Antigens for Cancer Vaccine Development.Vaccines · 2020Review
- Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.Journal of medical virology · 2020Article
- Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.Vaccines · 2020Article
- How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
- Erratum issuedCorrigendum.2017 · Cervera-Carascon, Victor [corrected to Cervera-Carrascon, Victor]
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
Abstract
Tolerance toward tumor antigens, which are shared by normal tissues, have often limited the efficacy of cancer vaccines. However, wild type epitopes can be tweaked to activate cross-reactive T-cell clones, resulting in antitumor activity. The design of these analogs (i.e., heteroclitic peptides) can be difficult and time-consuming since no automated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.